High-grade glioma before and after treatment with radiation and Avastin: Initial observations

Neuro-Oncology

Volumn 10, Issue 5, 2008, Pages 700-708

  Fischer, Ingeborg ^a,b   Cunliffe, Clare H ^a   Bollo, Robert J ^a   Raza, Shahzad ^a   Monoky, David ^a   Chiriboga, Luis ^a   Parker, Erik C ^a   Golfinos, John G ^a   Kelly, Patrick J ^a   Knopp, Edmond A ^a   Gruber, Michael L ^a   Zagzag, David ^a   Narayana, Ashwatha ^a  

^a NEW YORK UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Angiogenesis; Avastin; Bevacizumab; Biomarkers; Glioblastoma; Glioma

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CD34 ANTIBODY; FASCIN; IRINOTECAN; MONOCLONAL ANTIBODY D2-40; SMOOTH MUSCLE ACTIN; TEMOZOLOMIDE; VASCULOTROPIN A; ACTIN; ACTIN BINDING PROTEIN; ANGIOGENESIS INHIBITOR; CARRIER PROTEIN; CD34 ANTIGEN; MONOCLONAL ANTIBODY; VEGFA PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CELL MOTILITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLIOMA; HEMATOPOIETIC STEM CELL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MESENCHYME CELL; MULTIPLE CYCLE TREATMENT; PROTEIN EXPRESSION; TREATMENT OUTCOME; TREATMENT RESPONSE; BRAIN TUMOR; DRUG EFFECT; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; RADIATION EXPOSURE; RETROSPECTIVE STUDY; TUMOR RECURRENCE;

ACTINS; ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD34; BRAIN NEOPLASMS; CARRIER PROTEINS; COMBINED MODALITY THERAPY; FEMALE; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 56149110299     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2008-042     Document Type: Article

References (39)

1. Fischer I, Gagner JP, Law M, Newcomb EW, Zagzag D. Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol. 2005;15:297-310.
2. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25:581-611.
3. Ferrara N. VEGF as a therapeutic target in cancer. Oncology. 2005; 69(suppl):11-16.
4. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391-400.
5. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005;333:328-335.
6. Birner P, Piribauer M, Fischer I, et al. Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes. Brain Pathol. 2003;13:133-143.
7. Madconald D, Cairncross G, Stewart D, et al. Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group. Ann. Oncol. 1999;7:205-207.
8. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nature Rev Neurosci. 2007;8: 610-622.
9. Sund M, Xie L, Kalluri R. The contribution of vascular basement membranes and extracellular matrix to the mechanics of tumor angiogenesis. Apmis. 2004;112:450-462.
10. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol. 2004;165:35-52.
11. Mancuso MR, Davis R, Norberg SM, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest. 2006;116: 2610-2621.
12. Jubb AM, Hurwitz HI, Bai W, et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol. 2006;24:217-227.
13. Zahigaric L, Schliemann C, Bieker R, et al. Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity. Leukemia. 2007;21: 1310-1312.
14. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol. 2006;24:769-777.
15. Blumcke I, Giencke K, Wardelmann E, et al. The CD34 epitope is expressed in neoplastic and malformative lesions associated with chronic, focal epilepsies. Acta Neuropathol (Berl). 1999;97:481-490.
16. Blumcke I, Lobach M, Wolf HK, Wiestler OD. Evidence for developmental precursor lesions in epilepsy-associated glioneuronal tumors. Microsc Res Tech. 1999;46:53-58.
17. Reifenberger G, Kaulich K, Wiestler OD, Blumcke I. Expression of the CD34 antigen in pleomorphic xanthoastrocytomas. Acta Neuropathol (Berl). 2003;105:358-364.
18. Etzell JE, Keet C, McDonald W, Banerjee A. Medulloblastoma simulating acute myeloid leukemia: case report with a review of "myeloid antigen" expression in nonhematopoietic tissues and tumors. J Pediatr Hematol Oncol. 2006;28:703-710.
19. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med. 2001;7:1194-1201.
20. Hao HN, Zhao J, Thomas RL, Parker GC, Lyman WD. Fetal human hematopoietic stem cells can differentiate sequentially into neural stem cells and then astrocytes in vitro. J Hematother Stem Cell Res. 2003;12:23-32.
21. Wesseling P, Schlingemann RO, Rietveld FJ, Link M, Burger PC, Ruiter DJ. Early and extensive contribution of pericytes/vascular smooth muscle cells to microvascular proliferation in glioblastoma multiforme: an immuno-light and immuno-electron microscopic study. J Neuro-pathol Exp Neurol. 1995;54:304-310.
22. Haddad SF, Moore SA, Schelper RL, Goeken JA. Smooth muscle can comprise the sarcomatous component of gliosarcomas. J Neuropathol Exp Neurol 1992;51:493-498.
23. Rangdaeng S, Truong LD. Comparative immunohistochemical staining for desmin and muscle-specific actin: a study of 576 cases. Am J Clin Pathol. 1991;96:32-45.
24. Rodriguez FJ, Scheithauer BW, Jenkins R, et al. Gliosarcoma arising in oligodendroglial tumors ("oligosarcoma"): a clinicopathologic study. Am J Surg Pathol. 2007;31:351-362.
25. Ferreira LS, Gerecht S, Shieh HF, et al. Vascular progenitor cells isolated from human embryonic stem cells give rise to endothelial and smooth muscle like cells and form vascular networks in vivo. Circ Res. 2007;101:286-294.
26. Shibahara J, Kashima T, Kikuchi Y, Kunita A, Fukayama M. Podoplanin is expressed in subsets of tumors of the central nervous system. Virchows Arch. 2006;448:493-499.
27. Takei H, Bhattacharjee MB, Rivera A, Dancer Y, Powell SZ. New immunohistochemical markers in the evaluation of central nervous system tumors: a review of 7 selected adult and pediatric brain tumors. Arch Pathol Lab Med. 2007;131:234-241.
28. Mishima K, Kato Y, Kaneko MK, Nishikawa R, Hirose T, Matsutani M. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol (Berl). 2006;111:483-488.
29. Martin-Villar E, Megias D, Castel S, Yurrita MM, Vilaro S, Quintanilla M. Podoplanin binds ERM proteins to activate RhoA and promote epithelial- mesenchymal transition. J Cell Sci. 2006;119:4541-4553.
30. Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, Christofori G. Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell. 2006;9:261-272.
31. Adams JC. Roles of fascin in cell adhesion and motility. Curr Opin Cell Biol. 2004;16:590-596.
32. Shonukan O, Bagayogo I, McCrea P, Chao M, Hempstead B. Neurotrophin-induced melanoma cell migration is mediated through the actin-bundling protein fascin. Oncogene. 2003;22:3616-3623.
33. Vignjevic D, Kojima S, Aratyn Y, Danciu O, Svitkina T, Borisy GG. Role of fascin in filopodial protrusion. J Cell Biol. 2006;174:863-875.
34. Yamaguchi H, Inoue T, Eguchi T, et al. Fascin overexpression in intraductal papillary mucinous neoplasms (adenomas, borderline neoplasms, and carcinomas) of the pancreas, correlated with increased histological grade. Mod Pathol. 2007;20:552-561.
35. Tsai WC, Chao YC, Sheu LF, Chang JL, Nieh S, Jin JS. Overexpression of fascin-1 in advanced colorectal adenocarcinoma: tissue microarray analysis of immunostaining scores with clinicopathological parameters. Dis Markers. 2007;23:153-160.
36. Jin JS, Yu CP, Sun GH, et al. Increasing expression of fascin in renal cell carcinoma associated with clinicopathological parameters of aggressiveness. Histol Histopathol. 2006;21:1287-1293.
37. Xie JJ, Xu LY, Zhang HH, et al. Role of fascin in the proliferation and invasiveness of esophageal carcinoma cells. Biochem Biophys Res Commun. 2005;337:355-362.
38. Peraud A, Mondal S, Hawkins C, Mastronardi M, Bailey K, Rutka JT. Expression of fascin, an actin-bundling protein, in astrocytomas of varying grades. Brain Tumor Pathol. 2003;20:53-58.
39. Roma AA, Prayson RA. Fascin expression in 90 patients with glioblastoma multiforme. Ann Diagn Pathol. 2005;9:307-311.